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I. INTRODUCTION
The last half of the 2 0 h Century saw the emergence of the
"medical mass tort" as a legal construct, a media opportunity, and a
staple for products liability litigators. Drug and device litigation
spawned innovations in the law as it grappled with the complex is-
sues presented by each new product; market-share liability (DES
litigation), Daubert challenges (Bendectin litigation), and court-
appointed science panels (breast implant litigation)' are just a few
examples. But the issues faced by medical manufacturers in this
Century promise to be as interesting and as challenging as those of
the past. Patient privacy, marketing and promotional practices,
physician-industry conflicts of interest, the continuing evolution of
the learned intermediary doctrine, and reuse of "single-use" medi-
cal devices will be among the major themes of drug and device liti-
gation in the future.
II. ONLINE PHARMACEUTICAL SALES
The boom in e-commerce has generated expanded consumer
demand for prescription drugs over the internet. The convenience
of home delivery, along with the discounts offered by many phar-
macy sites, make online purchasing very appealing.4 Among the
benefits of online medication purchasing are:
-greater availability of drugs for shut-in people or those who
do not live near a pharmacy
-comparative shopping among sites in order to find the low-
est prices
-greater convenience and a larger variety of products
-greater, faster access to written information relating to
1. Sindell v. Abbott Laboratories, 26 Cal. 3d 588, cert. denied, 449 U.S. 912
(1980).
2. Daubert v. Merrell-Dow Pharms., Inc., 509 U.S. 579 (1994).
3. In re Breast Implant Litig., No. CV 92-P-10000-S (N.D. Ala. 1998)
4. Jeri Clausing, Online Pharmacies Try to Fend Off Government Regulation, N. Y
Times, March 21, 2000, at Al8.
[Vol. 27:1
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medications
-the privacy of buying medical products from home5
But the increased volume of online drug buying raises con-
cerns over the privacy of patient medical information, the physi-
cian's involvement (if any) in a patient's medication decisions,
and-as "rogue" sites selling "prescription-free" drugs proliferate-
the regulatory and legal compliance of suppliers.
A. Regulatory Overview
Enforcement of the laws and regulations that apply to online
pharmacies involves a tangle of state and federal agencies. Phar-
macies have traditionally been regulated by the states,7 but the
internet exceeds the reach of any one state's laws; while state agen-
cies can seek to enjoin online sites from doing business in their
state, they still remain open for business in the other 49 states. Fur-
ther, while more scrupulous sites like Drugstore.com have obtained
pharmacy licenses in all 50 states,8 others are licensed in just one-
but sell to all comers, in whatever state they reside. To avoid
charges of practicing medicine and dispensing drugs without a li-
cense in the other states, these sites argue that a customer, by visit-
ing the site, actually enters the state where the site is licensed.9
This argument has yet to be tested in court, however.
Given the limited powers of the state agencies, the FDA and
the Federal Trade Commission play key roles at the national level
by regulating drug claims and enforcing the Food, Drug, and Cos-
metic act. Customs and the Postal Service also help regulate
shipments of drug products." But regulating Internet pharmacy
sites, as an online seller of Viagra put it, is "kind of like trying to
nail Jell-O to a wall."" Sites can show up on the Web and then dis-
5. John Henkel, Buying Drugs Online, 34 FDA Consumer 25, 26 (January-
February 2000).
6. Id. at 27.
7. Jeri Clausing, Online Pharmacies Try to Fend Off Government Regulation, N.Y.
Times, March 21, 2000, at Al8.
8. Id.
9. Sheryl Gay Stolberg, In Internet Drug Deals, a Regulation Dilemma, N. Y.
Times, June 27, 1999, www.nytimes.com/library/tech/99/06/biztech/articles/-
/27net.html.
10. John Henkel, Buying Drugs Online, 34 FDA Consumer 25, 27 (January-
February 2000).
11. Id.
12. Sheryl Gay Stolberg, In Internet Drug Deals, a Regulation Dilemma, N.Y
Times, June 27, 1999.
20001
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appear overnight. In many cases, all that is needed to set up an
online drugstore is a valid doctor's license, a relationship with a
drug wholesaler, and a credit card, making regulatory oversight the
equivalent of trying to hold back the ocean with a dike made of
sand. 13
B. The Absence Of A "Learned Intermediary"
Many of the "online pharmacies" only require purchasers to fill
out a questionnaire to obtain medications, bypassing the traditional
requirement of a physician's prescription. Such sites usually claim
that questionnaires are reviewed by a doctor-but rarely is any in-
formation provided about who the doctor is and what his or her
credentials are.14 Most of the time, patients do not learn who their
doctors are until the drugs arrive in the mail.'5 Further, if a con-
sumer is convinced that he or she needs a particular treatment,
questionnaire answers may be falsified with relative ease." Thus,
while the questionnaire may save a trip to the doctor's office, the
time savings is very likely outweighed by the increased risk of harm.
According to Jeffrey Shuren, M.D., a medical officer in the FDA's
Office of Policy, Planning, and Legislation, "Patients risk obtaining
an inappropriate medication and may sacrifice the opportunity for
a correct diagnosis or the identification of a contraindication to the
drug.""
An example shows just how grave the consequences can be. In
Illinois, a 52-year-old man with a history of chest pains and a family
history of heart disease bought Viagra from a site only requiringS . 18
that he fill out a questionnaire. The man later died of a heart at-
tack. 9 While no connection between the drug and the man's death
has been shown, it is nevertheless unlikely that he would have been
able to obtain the drug had he seen his doctor, given his cardiac
risk factors. 20 This scenario raises the question whether the manu-
13. Id.
14. John Henkel, Buying Drugs Online, 34 FDA Consumer 25, 27 (January-
February 2000).
15. Sheryl Gay Stolberg, In Internet Drug Deals, a Regulation Dilemma, N.Y.
TimesJune 27, 1999.
16. John Henkel, Buying Drugs Online, 34 FDA Consumer 25, 27 (January-
February 2000).
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facturer should have any liability when the decedent would not
have received the drug had he sought it through legal channels.
The pharmacy industry has recently undertaken efforts at self-
regulation in order to impose accountability and quality assurance
on Internet sales of prescription drugs. The National Association
of Boards of Pharmacy (NABP) recently introduced a certification
program, '"Verified Internet Pharmacy Practice Sites" or "VIPPS.
21
Certification under VIPPS requires online pharmacy sites to main-
tain all their state licenses in good standing, to allow information
about them to be posted on the VIPPS website, and to allow inspec-
22tions by the NABP. The VIPPS certification program is the "car-
rot" offered by the NABP; but they appear ready to wield the stick if
necessary. According to Carmen Catizone, executive director of
the organization, "Any site that uses a questionnaire without a le-
gitimate patient-physician relationship, we consider illegal."
23
The American Medical Association ("AMA") is also taking
steps to remedy the lack of standards governing online prescribing.
At its June, 1999 annual meeting, the AMA discussed guidelines
dealing specifically with Internet prescriptions, which included a
requirement that patients first receive an in-person physical exami-
24nation. Manufacturers voiced support for the AMA's efforts. Mar-
tin Hirsch, public affairs director for Roche, makers of Xenical -a
popular weight-loss drug frequently sold at sites not requiring a
prescription-indicated that "[t]he relationship between physician
and patient is critically important" and expressed Roche's support
for "guidelines that will ensure that this relationship continues.,
25
Manufacturers are clearly concerned about the liability impli-
cations of consumers buying their products without a doctor visit.
Not only will the practice result in injuries stemming from inap-
propriate prescriptions, it will bring increased pressure to provide
direct warnings to consumers, where now manufacturers need only
warn doctors under the "learned intermediary" doctrine. In Au-
gust, 1998, when the Viagra craze was in full swing, Pfizer filed a
complaint with the Federal Trade Commission alleging that online
sites are deceiving consumers by ignoring the label's advice that the
21. Id. at 29.
22. Id.
23. Sheryl Gay Stolberg, In, Internet Drug Deals, a Regulation Dilemma, N.Y.
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26
drug be prescribed only after a physical examination.
C. Illegal Off-Shore Drug Sales
Recognizing the regulatory slipperiness of online drug sales,
the Clinton administration is seeking more Federal oversight of
online drugstores.27  The President is requesting legislation that
would require online drug sellers to get FDA approval before
transacting sales on the Web. 2s The legislation would also create
civil penalties of up to $500,000 for selling drugs without a pre-
scription or without FDA certification. 29 The administration is also
seeking $10 million from Congress to beef up its enforcement of
online drug sales. °
But increased regulation at the Federal level may only result in
more sites moving their operations overseas, joining the numerous
foreign "pharmacies" already online selling drugs unavailable with-
out a prescription-or unavailable altogether-in the U.S. Accord-
ing to Customs Service Commissioner Raymond W. Kelly, "Em] any
of these internet pharmacies are fly-by-night operations set up over-
seas to avoid U.S. law. They have little regard for patient safety.,
31
Many of the sites also sell products that are either different from
those approved in the U.S. or are past their expiration dates.32 Im-
ported drugs may be especially dangerous, according to one Cus-
toms official, because "[a] lot of this stuff is being cooked up in
somebody's back room in Thailand" and "may be laced with all
sorts of contaminants.
3 3
The U.S. and Thai governments recently joined forces to shut
down seven prescription-drug-selling web sites operating in Thai-
land, the first-ever bust of a foreign online drug-selling operation. 4
26. Sheryl Gay Stolberg, In Internet Drug Deals, a Regulation Dilemma, N.Y
Times, June 27, 1999.
27. Jeri Clausing, Online Pharmacies Try to Fend Off Government Regulation, N.Y.
Times, March 21, 2000.




31. Robert Pear, Thais Help U.S. Stem Internet Sales of Medicines, N.Y Times,
March 21, 2000.
32. John Henkel, Buying Drugs Online, 34 IDA Consumer 25, 27 (January-
February 2000).





William Mitchell Law Review, Vol. 27, Iss. 1 [2000], Art. 25
http://open.mitchellhamline.edu/wmlr/vol27/iss1/25
DRUG AND DEVICE LITIGATION
One of the Thai sites, Vitality Health Products, advertised "pre-
scription-free pharmaceuticals by e-mail at incredibly low prices"
and sold popular drugs like Minoxidil, Propecia, Viagra, Retin-A,
and Premarin.3 5 The Website even advised customers what to do in
the event customs seized their shipment:
The bust, orchestrated by Thai police and the Thai equivalent
of the FDA, netted 20 computers, 245 parcels destined for the U.S.,
and more than 2.5 million pounds of drugs-including anabolic
steroids, Valium, Viagra, fen-phen, Tylenol with codeine, and
Xanax.37 But the Thai operations appear to have been the tip of
the iceberg. Numerous similar sites continue selling prescription
drugs unabated from bases in Mexico, Switzerland, Britain, New
38Zealand, and elsewhere. Customs seized nearly 10,000 packages
containing prescription drugs in 1999, 4.5 times more than in the
previous year. The drugs seized either had not been approved in
the U.S., did not comply with FDA labeling requirements, or fell
below federal standards for the quality and purity of drugs. 9
Customs acknowledges that the number of pills seized proba-
bly represents only a fraction of the total volume of prescription
drugs being imported due to Internet sales. Frequently the orders
are sent in nondescript packages that do not declare their contents,
making detection difficult.4' And enforcement resources are lim-
ited: a spokesman for Customs indicates that the agency usually re-
frains from taking action when consumers import small amounts of
drugs, noting that "[w] e won't arrest Granny just because she wants
to get her drugs cheaper.,
42
The illegal sale of expired or contaminated products, often
without prescription, may create complex products liability issues
for drug manufacturers, such as:
To what extent are manufacturers responsible for injuries suf-
fered by people who obtained their drugs illegally?




38. Id. One site, "Direct Response Marketing," runs its operations from the
Channel Islands. http://www.directresponsemarketing.co.uk/.
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channels when they become aware of them?
What liability, if any, does a manufacturer have for injuries re-
sulting from its product when the product has been contaminated
or "laced" with another substance by a third party outside normal
distribution?
Can the "learned intermediary" defense still be used if there
was no intermediary?
Does the manufacturer have a duty to warn these users di-
rectly, even though obtaining the drug without a doctor's prescrip-
tion is illegal?
Courts will increasingly have to confront these thorny ques-
tions as illegal on-line sales of prescription drugs continue to grow.
D. Privacy
The confidentiality of private medical information will become
a greater concern as more and more prescriptions are filled over
the Web. One of the most popular uses of the Internet is for
health information, and this has led many web-users to submit per-
sonal medical information to unsecured chat-rooms and health-
related sites.43 In addition, doctors and patients are increasingly
communicating by e-mail; hospitals are providing patients access to
their medical records on-line; and some health plans are even en-
rolling new members over the Internet. 4 While many of the larger
sites use secure servers and encrypt personal information, more
marginal sites do not. In this manner, personal health information
can become accessible to insurance companies, would-be employ-
ers, and others who could use it to their advantage.
Of particular concern with respect to online drug purchases
are "cookies," which many retail websites use to track the buying
habits of visitors to their sites. 5 While "cookies" can provide con-
sumers the convenience of information and products tailored to
their interests, and eliminate the need for a log-in with every visit to
the site, they could also show that a customer was buying a particu-
lar drug on a continuing basis. In this manner, a customer's buying
habits could reveal that he has the virus that causes AIDS, or suffers
from depression, impotence, or any number of other conditions he
43. Milt Freudenheim, Privacy a Concern as Medical Industry Turns to Internet,
N.Y Times, August 12, 1998.
44. Id.
45. Margaret A. Winkler, M.D., et al., Guidelines for Medical and Health Informa-
tion Sites on the Internet, 283JAMA 1600, 1605 (2000).
[Vol. 27:1
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would rather have kept private.46
Privacy issues do not present a significant liability concern for
drug and device manufacturers, who are usually blind to the identi-
ties of end-users of their products. Retailers, however, could end
up paying steep damages awards if they seek to profit from the sale
of confidential medical information, or otherwise fail to protect the
privacy of their customers.
III. DIRECT-TO-CONSUMER ADVERTISING: DEATH-KNELL FOR THE
LEARNED INTERMEDIARY DOCTRINE?
Relationships among healthcare manufacturers, doctors, pa-
tients, and payers have been transformed in recent years by in-
creased competition, the cost-sensitivities of managed care, and
growing patient involvement in health care decisions. In particu-
lar, the old hierarchy for communicating information about pre-
scription drugs-from manufacturer to doctor to patient-is being
subverted. In the era of managed care, physicians no longer con-
trol demand for prescription drugs to the degree they once did;
they must answer to their employers and to payers, who often are
reluctant to try new products-particularly if the cost of the new
treatment is higher than its predecessor. Therefore, recognizing
that consumers are more than ever driving the demand for pre-
scription drugs, manufacturers are increasingly promoting their
products directly to public and bypassing the "filter" traditionally
applied by the medical community.
A. Regulatoiy Requirements
FDA regulates prescription drug advertising for the accuracy• 47
and adequacy of their content. While accuracy is a relatively
straightforward requirement, adequacy can be more complex. The
Food, Drug and Cosmetic Act requires that advertisements for pre-
scription drugs include information "in brief summary" relating to
48
side effects, contraindications, and effectiveness of the drug. By
the time a manufacturer has complied, however, the summary is of-
ten far from brief. Other code provisions direct that the brief
summary must disclose side effects, contraindications, warnings,
46. Milt Freudenheim, Privacy a Concern as Medical Industry Turns to Internet,
N.Y. Times (August 12, 1998).
47. See generally 21 C.F.R. § 202.1.
48. 21 U.S.C. § 352(n)(3)(2000).
20001
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and precautions under the headings "cautions," "special considera-
tions," "important notes," and "effectiveness. 4 9 At the end of the
day, the "brief summary" generally must include all of the language
50contained in the product's package insert.
This language, commonly provided in eye-straining "mouse-
print," is lengthy, technical, and detailed to the point of incompre-
hension for the average layperson. In fact, the technical nature of
this language is one of the main reasons for the learned intermedi-
ary rule-only a physician is properly qualified to understand, di-
gest, and translate such highly technical information in terms her
patients can understand.
The regulations for advertising prescription drugs through
broadcast audio such as television or radio modify the disclosure
requirements. Recognizing that the length of a "brief summary"
would make radio and television advertising impossible, FDA lim-
ited the disclosure requirements in the broadcast media to a "major
statement" of the risks attendant to the therapy.5' Also, in lieu of
presenting a "brief summary" in connection with the ad, a sponsor
may provide a way for the viewer to obtain the approved package
labeling outside the broadcast presentation." This alternative is
known as "the adequate provision" requirement.
While the adequate provision requirement made broadcast ad-
vertising more accessible to drug and device manufacturers on pa-
per, manufacturers did not seize the opportunity because FDA was
silent on how the requirement could be satisfied. Without some as-
surances from the agency, manufacturers found the risk that their
advertising would be found in violation of the FDCA-which would
lead their product to be considered "misbranded" and subject to
seizure-were simply too great.
Thus, in August of 1997, FDA addressed manufacturers' fears
by publishing a draft guidance entitled "Consumer-Directed
Broadcast Advertisements," which sets out criteria for the "adequate
provision" of labeling information.5 ' The agency issued the final
guidance, which does not differ substantially from the draft, on
49. 21 C.F.R. §§202.1(e) (1), (e) (3) (iii).
50. See generally 21 C.F.R. § 202.1 (e) (3), (e)(4).
51. 21 U.S.C. § 202.1(e)(1).
52. Id.
53. Final Guidance for Industry; Consumer-Directed Broadcast Advertisements;
www.fda.gov/cder/guidance/1804fnl.pdf; see also FDA Talk Paper, FDA Issues Final
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August 6, 1999. 54 In the guidance suggests a four-part approach:
1. The ad should include a toll-free telephone number for
consumers to call for the approved package labeling.55 Following
their call, consumers should be given the choice of receiving the
labeling by mail, fax, or by having it read to them over the phone.
56
2. The ad should indicate that additional product information
is available in print advertisements or brochures. 5' This provides a
mechanism for consumers who do not have internet access to ob-
tain the labeling. Thus, the broadcast ad could refer consumers to
a print ad containing a "brief summary," or direct them to bro-
chures available at doctors' offices, libraries, and pharmacies.
3. The ad should state that pharmacists and/or physicians may
provide additional product information to consumers.
4. The ad should provide an internet address, either during
the broadcast or throuh the toll-free number, where consumers
can access the labeling.
An ad containing these elements should meet the "adequate
provision" requirement, assuming it also includes a thorough "ma-
jor statement" conveying the product's most significant risks.
B. Implications Of Direct Advertising For The Learned Intermediary
Doctrine
In the old marketing regime, prescription products were only
marketed to physicians, and only physicians received warnings in-
formation about the product. This was consistent with the princi-
ples underlying the learned intermediary doctrine, through which
a manufacturer discharges its duty to warn by informing physi-
cians-and not health-care consumers-of risks associated with the
medication. 59 Where products are the subject of direct advertising,
however, the applicability of these principles is called into question.
The learned intermediary doctrine assumes that consumers
54 Final Guidance for Industry; Consumer-Directed Broadcast Advertisements;
www.fda.gov/cder/guidance/1804fnl.pdf; see also FDA Talk Paper, FDA Issues Final
Guidance for Direct-to-Consumer Rx Drug Advertisements (August 6, 1999),
www.fda.gov/bbs/topics/ANSWERS/ANS00968.html
55. Id. at 2.
56. Id.
57. Id. at 2-3
58. Id. at 2.
59. Joseph G. Blute, Courts Struggle with Learned Intermediary Rule Exceptions, XV
Leader's Product Liability Law & Strategy 3 (May 1997).
2000]
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must have a doctor navigate them through the complex medical
and scientific issues presented by prescription drug treatment.
Thus, the manufacturer's duty is limited to providing adequate
warnings to the physician, who has a corresponding duty to trans-
late that information in terms that her patients will understand.
Exceptions to the doctrine have emerged over the years with
respect to mass immunizations, oral contraceptives, and Intrauter-
60ine contraceptive devices (IUDs). Courts have reasoned that since
mass immunizations are not usually administered by physicians, lit-
tle specialized information is conveyed to the patient, and there-
fore manufacturers must warn consumers directly of any risks. 6'
With respect to oral contraceptives and IUDs, courts have held that
since patients ultimately decide for themselves which form of birth
control to use, they must be warned directly in that instance as
well.62
The rationale behind each of these exceptions is that the con-
sumer, and not the physician, ultimately drives the decision
whether to obtain the product, and that the doctor's role in provid-
ing specialized information is diminished. This rationale is cited in
support of arguments that manufacturers lose the learned inter-
mediary defense when they engage in direct-to-consumer advertis-
ing.
1. Some Courts Consider DTC Advertising Another Exception To
The Learned Intermediary Doctrine
Edwards v. Basel Pharmaceuticals63 is an example of a case where
the court held DTC advertising was an exception to the learned in-
termediary doctrine. In Edwards, the decedent suffered a fatal
heart attack which allegedly resulted from overuse of a nicotine
patch. The package insert specifically disclosed the risk of death
from overdose, but the direct-to-patient warnings did not. The
manufacturer asserted that, consistent with the learned intermedi-
ary doctrine, its liability for failure-to-warn could only be assessed
with respect to the physician-directed package insert.
The Oklahoma Supreme Court disagreed. Despite the full




63. 933 P.2d 298 (Okla. 1997).
[Vol. 27:1
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When direct warnings to the user of a prescription drug
has been mandated by a safety regulation promulgated for
the protection of the user, an exception of the learned in-
termediary doctrine exists, and failure on the part of the
manufacturer to warn the consumer can render the drug
unreasonably dangerous. 64
In Shanks v. Upjohn Co.,65 a case involving the drug Xanax, the
court held that prescription products where patients initiate the
usage, where drugs are typically administered in a clinical setting
with little patient input or where drugs marketed under a strategy de-
signed to appeal directly to the consuming public are areas where courts
have held that manufacturers have a duty to warn patients di-
rectly.
66
In In Re Norplant Contraceptive Products Liability Litigation,67 a
federal court in Texas held that the defendant's direct advertising
campaign for Norplant, an implantable contraceptive, did not
eliminate the learned intermediary defense because the plaintiffs
never saw any of the ads before receiving their implants. But the
court did not address the question "[w]hether a drug manufac-
turer's use of direct-to-consumer advertising is ever grounds for cre-
ating an exception to the learned intermediary doctrine," indicat-
ing that "This is an issue which should be resolved by the Texas
Supreme Court."68
Finally, in another Norplant case, Perez v. Wyeth Laboratories,
Inc.,69 the New Jersey Supreme Court held that direct-to-consumer
advertising creates an exception to the learned intermediary rule.
The Court expressed its view that "Our medical-legal jurisprudence
is based on images of health care that no longer exist" in ruling
that the underpinnings of the learned intermediary doctrine are
absent in the context of consumer-directed advertising."' Unlike in
the past, doctors have less time to discuss risks with patients, and
drug companies have much greater access to consumers through
direct advertising; therefore, the Court reasoned, manufacturers
should be held liable if their advertising fails to provide adequate
64. Id.
65. 835 P.2d 1189 (Alaska 1992).
66. Id. at 1195, n.7.
67. 955 F. Supp 700 (E.D. Tex. 1997).
68. Id. at 708, n. 45 (emphasis added).
69. 734 A.2d 1245 (N.J. 1999).
70. Id. at 1246, 1255.
2000]
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warnings. 71 The Court did suggest, however, that compliance with
FDA regulations governing consumer-directed advertising would be
a defense to a failure-to-warn claim.2
2. Despite These Holdings, The Learned Intermediary Doctrine Is
Still Alive In Most Jurisdictions
In Polley v. Ciba-Geigy Corporation,7 ' a federal court in Alaska ap-
plied the learned intermediary doctrine despite direct communica-
tions in patient brochures. The court held that the brochures did
not create an exception to the learned intermediary rule. Mikell v.
Hoffman-LaRoche, Inc.14 held similarly. There, an informational
pamphlet identifying some, but not all risks associated with the
drug Accutane did not void the learned intermediary defense since
the plaintiffs prescribing physician was aware of the risk when he
wrote the prescription.
In Presto v. Sandoz Pharmaceuticals Corporation, the Georgia
Court of Appeals concluded that a pamphlet entitled, "Understand-
ing Clozaril (Clozapine) Therapy: A Guide For Patients And Their
Families," did not nullify the learned intermediary doctrine be-
cause the plaintiffs could not have reasonably relied on the pam-
phlet for warnings concerning the dangers of the use of Clozaril.
According to the court, "[t] he pamphlet does not constitute an ef-
fort to inform patients of all the dangers of Clozaril and does not
purport to do so....The booklet states that it 'provides answers to
many questions about Clozaril' but cautions the reader 'if there are
other questions about Clozaril therapy, be sure to ask the doctor,
nurse or pharmacist.'
76
These decisions seem more in tune with health-care decision-
making today. Even with the increase in information available di-
rectly, consumers still need a doctor to balance the benefits against
the risks and to provide expert advice on whether the therapy is
appropriate. While direct advertising creates a more educated pub-
lic, it can never replace the particularized information that physi-
cians provide, and it therefore should not relieve doctors of their
duty to inform their patients.
71. Id. at 1255-57.
72. Id. at 1259.
73. 658 F. Supp. 420 (D. Alaska 1987).
74. 649 So. 2d 75 (La. Ct. App. 1994).
75. 487 S.E.2d 70 (Ga. 1997).
76. Id. at 74.
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C. A Related Issue: "Med Guides"
The issue of manufacturers' responsibility to provide warnings
to consumers arose before the ascendance of direct-to-consumer
advertising. In 1995, FDA proposed a rule that would require
manufacturers to produce "med guides" for their products, along
the lines of the "Nutrition Facts" labeling provided on food prod-
ucts." The guides would have replaced the often inconsistent pam-
phlets provided by pharmacies, and their language would have re-
quired FDA approval."
Faced with strong protests from pharmacies and drug compa-
nies concerned about the increased liability the "med guides"
would create, Congress rejected the comprehensive plan 
in 1997. 7,
But FDA has recently gone forward with a less ambitious plan to
require such guides for 10 drugs it considers particularly dangerous
in a given year."° Further, under new Department of Health and
Human Services regulations, 75% of all prescriptions must come
with leaflets containing "useful information" by the end of 2000,
and 95% by 2006-otherwise, FDA promises to reintroduce its med
guides plan.8' As doctors, under pressure from managed care pay-
ers, have less and less time to discuss risks of medications with their
patients, Congress may have no choice but to adopt the program
the next time around. Clearly, the consequences would be grave
for the learned intermediary doctrine.
IV. DISSEMINATING INFORMATION ON OFF-LABEL USES: ILLEGAL
PROMOTION, OR FREE SPEECH?
The increased volume of drug and medical device advertising
belies the fact that medical products marketing is often a regulatory
high-wire act. When FDA approves a medical device or pharma-
ceutical, it allows sale of the product for the approved indications
and for those indications only. Thus, although doctors frequently
discover new and highly beneficial uses of approved products, drug
and device companies are not allowed to market the products for
those uses without going through the FDA approval process all over
77. 60 FR 44181 (August 24, 1995); see also Sheryl Gay Stolberg, FDA Pushes for
Prescription Drug Guides, N.Y. Times, June 4, 1999.
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again.8 2 Doctors, however, remain free to prescribe medication for
unapproved uses, a practice known as "off-label use."" For exam-
ple, doctors for years have prescribed aspirin in order to reduce the
risk of heart attacks, but this "off-label" use was not actually ap-
proved by FDA until 1998.84 The pharmaceutical industry estimates
that anywhere from 25% to 60% of the 1.6 billion prescriptions
815written annually are for off-label uses.
Sometimes doctors who discover such beneficial "off-label"
uses publish their results, so that others in the health care commu-
nity may benefit. But when a manufacturer provides a doctor with
such articles, is the manufacturer "promoting" its product for the
off-label use? Or is the manufacturer merely exercising its free-
speech right to provide the doctor with truthful information?
A. Round 1: Washington Legal Foundation vs. Friedman
86
For the last five years, FDA has taken a strict stance that a
manufacturer's mere distribution of information on off-label uses-
even without any endorsement or comment of any sort-constitutes
illegal marketing and renders the product in question "mis-
branded." It took this stance in three separate publications:
-Guidance to Industry on Dissemination of Reprints of Cer-
tain Published, Original Data, 61 FR 52800 (October 8, 1996);
-Guidance for Industry Funded Dissemination of Reference
Texts, 61 FR 52800 (October 8, 1996); and
-Final Guidance on Industry Supported Scientific and Educa-
tional Activities, 62 FR 64074 (December 3, 1997).
In Washington Legal Found. v. Friedman, the Washington Legal
Foundation ("WLF"), a non-profit organization favoring reduced
government regulation, sued the Agency on the ground that the
three guidance documents infringed on drug and device manufac-
turers' First Amendment rights.
WLF argued that the speech in question concerned academic
and scientific research, and was therefore entitled to the highest
First Amendment protection; the FDA responded that the guid-
82. 21 U.S.C. § 321 (p).
83. 59 FR 59820-21 (November 18, 1994).
84. Jim Oliphant, FDA's New Drug War Industry Fights For Alternative Uses of Ap-
proved Productivity, Legal Times, January 10, 2000.
85. Id.
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ances did not implicate the First Amendment, but if they did, the
speech at issue was "commercial" and should not be granted the
protection of "pure" speech.8' First, the Court held that the guid-
ances did constitute speech meriting some level of protection, not-
withstanding FDA's argument that its broad regulatory authority
empowered it to regulate without running afoul of the First
Amendment. s9 Then, while recognizing that the dissemination of
off-label use information is "one of those complex mixtures of
commercial and non-commercial elements," the court found the
manufacturers' activities essentially promotional and worthy of only
the qualified protection afforded commercial speech under Central
Hudson Gas v. Public Service Comm'n of New York. 447 U.S. 557
(1980)."
Applying the Central Hudson Gas test, Judge Lamberth held:
1) that dissemination of off-label information is neither unlaw-
ful nor inherently misleading;
2) that the government has a substantial interest in protecting
the health of its citizens and in requiring manufacturers to submit
off-label uses for FDA approval;
3) that the guidance documents advance the government's
substantial interests; but
4) that the guidance documents are unconstitutional because
they are more extensive than necessary.91
Thus, the court found that "[t]hrough the government's well-
intentioned efforts to prevent misleading information from being
communicated, a great deal of truthful information will also be
embargoed. 9 2 According to Judge Lamberth, an "obvious" and less
restrictive alternative to the Continuing Medical Education
("CME") guidances-which would have prohibited manufacturers
from distributing articles on off-label topics-is to allow the distri-
bution but with "full, complete, and unambiguous disclosure by the
manufacturer" that the materials concern an off-label use.9  Based
on this reasoning, he issued an injunction barring FDA from limit-
ing "any pharmaceutical or medical device manufacturer or any
other person":
88. Id. at 59.
89. WLF I at 59-61.
90. Id. at 62-65 (citations omitted).
91. Id. at 65-74.
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... from disseminating or redistributing to physicians or
other medical professionals any article concerning pre-
scription drugs or medical devices previously published in
a bona fide peer-reviewed professional journal, regardless of
whether such article includes a significant or exclusive focus on
uses of drugs or medical devices other than those approved by
FDA ..94
B. Round 2: Washington Legal Foundation vs. Henney95
The Guidance documents at issue in WLFIwere superseded by
the passage of the Food and Drug Modernization Act of 1997
("FDAMA"), which contains specific provisions governing manufac-
turer distribution of information on off-label uses. Since the
FDAMA came into effect after Judge Lamberth issued his injunc-
tion, FDA argued that the injunction should be modified to ex-
clude FDAMA and its implementing regulations from the injunc-
tion's scope. The Judge instead amended the injunction to clarify
that the FDAMA provisions and related regulations, which were es-
sentially the same as the three guidance documents at issue before,
were also unconstitutional.96
One subtle change instituted by the FDAMA was to permit
manufacturers to distribute off-label information, so long as they
made an application to FDA to have the use approved within a
short time of the distribution. But Judge Lamberth hardly agreed
that this removed the taint from the statute:
The supplemental application requirement of the act amounts
to a kind of constitutional blackmail-comply with the statute or
sacrifice your First Amendment rights. It should go without saying
that this tactic cannot survive judicial scrutiny.97
Thus, he concluded that the injunction should not be cur-
tailed, but rather expanded to include the FDAMA and its imple-
menting regulations.
C Round 3: FDA Retreats - And Wins?
By what some would consider a legal Houdini-act, FDA man-
94. Id.
95. 56 F. Supp. 2d 81 (D.D.C. 1999) (hereinafter W FIf).
96. Id. at 82.
97. Id. at 87.
98. Id. at 88.
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aged to escape the full impact of Judge Lamberth's decisions and
injunctions in VVLF I and VLF H at the Court of Appeals. In argu-
ment before the D.C. Circuit, the Agency essentially stipulated that
the FDAMA, along with its guidance on industry-supported CME,
did not provide it with independent authority to prohibit dissemi-
nation of information about off-label uses of drugs and medical de-
vices. The Court of Appeals therefore found, and WLF agreed, that
there was no longer a First Amendment issue to be decided, and
vacated Judge Lamberth's decisions and injunctions in VLFIand /
to the extent they declared FDAMA and the CME guidance uncon-
stitutional. 99 In partly vacating the district court's orders, the D.C.
Circuit made it clear that "[w] e certainly do not criticize the rea-
soning or conclusions of the district court.. .we do not reach the
merits of the district court's First Amendment holdings and part of
its injunction still stands."'00 What the Court did not make clear,
though, is which part of the injunction remains standing.
FDA did not "fall on its sword" before the Court of Appeals for
no reason. It is now apparent that the agency conceded that
FDAMA and the CME guidance do not independently allow speech
restrictions in order to preserve a foothold, however tenuous, for
maintaining regulatory authority over information about off-label
uses. Thus, in spite of the Appeals Court's approbation (albeit in
dicta) of Judge Lamberth's reasoning, the Agency remains loyal to
its original position, insofar as it intends to use non-compliance
with FDAMA and the CME guidance as evidence in "misbranding"
actions against manufacturers. The D.C. Circuit's opinion supports
the agency's authority to proceed in this manner, holding that
"[t]he FDA retains the prerogative to use both types of arguably
promotional conduct as evidence in a misbranding or 'intended
use' enforcement action."' 0' Consequently, even though the agency
may not be able to prevent manufacturers from distributing infor-
mation about off-label uses, it may still argue that such distribution
indicates an intent to promote a use other than the uses in the ap-
proved labeling-unless, of course, the distribution falls within the
boundaries established by FDAMA and the CME guidance. At the
same time, the Agency recognizes that a manufacturer may have a
First Amendment defense in a "misbranding" action based on non-
99. Washington Legal Found. vs. Henney, 202 F.3d 331 (D.C. Cir. 2000).
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compliance with these requirements. 12
Under these circumstances, even though the agency's conces-
sion is an apparent victory for WLF, the organization remains cir-
cumspect about FDA's intent to comply with the spirit of Judge
Lamberth's decisions. WLF Chief Counsel Richard Samp indicated
that " [w] e will be keeping a close eye on FDA; the very first time
FDA so much as suggests that manufacturers could be sanctioned
for distributing truthful information of the type covered by the in-
junction, we will be back in district court seeking to have FDA held
in contempt."
10 3
The Agency has now made the first such suggestion, reiterat-
ing its position in the Federal Register of March 16, 2000 that the
FDAMA and the CME guidance establish a "safe harbor" for manu-
facturers who comply with them, but insisting that it may still use a
manufacturer's non-compliance as evidence of a medical product's
true "intended use" in an action for misbranding.104 WLF disagrees
with this interpretation and reportedly intends to make a motion to
enforce Judge Lamberth's earlier order, which in WLF's view still
bars the agency from prohibiting the dissemination of information
on off-label uses. Clearly, the fight isn't over; quite possibly it has
just begun.
V. INDUSTRY GIFTS To PHYSICIANS: SUPPORTING INNOVATION OR
"BUYING SCIENCE"?
As medical device and pharmaceutical manufacturers have in-
tensified their marketing efforts, they have developed new ways to
broaden their relationships with doctors. The orthopedic bone
screw litigation of the late 1990's illustrates the perils of these mar-
keting strategies if the product later becomes the subject of litiga-
tion.
The bone screw litigation involved more than 2,000 civil ac-
tions from all over the country that were consolidated for pre-trial
purposes in the U.S. District Court for the Eastern District of Penn-
sylvania. 115 The plaintiffs claimed to have suffered injuries from al-
legedly defective rods, plates, and screws placed in their spine in
102. 65 FR 14287 (March 16, 2000).
103. WLF Press Release, Appeals Court Affirms Injunction Against FDA Speech Re-
strictions, at <http://www.wlf.org/pressrel.htm> (last visited Feb. 11, 2000).
104. 65 FR 14287 (March 16, 2000).
105. In re Orthopedic Bone Screw Litig., 193 F. 3d 781, 784 (3d Cir. 1999).
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order to alleviate their severe back conditions. °6 But more than a
year after the first complaints were filed, the plaintiffs expanded
their claims beyond the well-worn products liability theories typi-
cally found in medical mass torts. In these "Omni" actions, the
plaintiffs alleged that the manufacturers, certain medical profes-
sional associations, and individual doctors conspired to hoodwink
the FDA and defraud hundreds of orthopedic surgeons who would
not have implanted the devices into the plaintiffs had they known
the real risks of the procedure.' ° The allegations amounted to a
claim that the device industry and the medical profession had con-
spired to "buy the science" that would support ongoing sales of
bone screw devices.
The alleged conspiracy was based on agreements between the
manufacturers, the medical associations, and the doctors that the
doctors would make presentations on spinal fixation of the de-
vice-an unapproved, "off-label" use-in exchange for royalties re-
lating to sales of the product and for shares in the manufacturers'
companies.'O" According to the complaints, although the seminars
did not on the surface appear different from other CME programs,
they really amounted to "Tupperware parties" since their purpose
was purely commercial.1 9 The doctors did not disclose to seminar
attendees that the procedure they were demonstrating was "off-
label" and not approved by the FDA, nor did they disclose their di-
rect financial interest in the success of the product and the com-
pany that made it.""
While the "Omni" conspiracy claims were dismissed with
prejudice,"' they nevertheless are significant as a first salvo fired
into uncharted territory. The manufacturers, medical associations,
and doctors named in the suits spent millions fending them off.
The suits also exposed the extent to which industry promotional
practices pervade continuing medical education events, a revela-
tion that is troubling to many. While the plaintiffs' bar lost this
time, they no doubt learned valuable lessons in the bone screw liti-
gation-lessons that could reverse their fortune the next time
around.
106. Id.
107. Id. at 786.
108. Id.
109. Id.
110. Id. at 786-77.
111. Id. at 792.
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A. Influence In Practice: TheJAMA Study On Physician Gifts And
Prescribing Practices
One piece of evidence that future conspiracy plaintiffs will
likely use is a January, 2000 study published in the Journal of the
American Medical Association on the influence of gifts on physicians'
prescribing practices.1 2 The study, a compilation of data from 538
other studies on the subject, resulted in the following startling con-
clusions:
Meetings with pharmaceutical representatives were associated
with requests by physicians for adding the drugs to the hospital
formulary and changes in prescribing practice.
Drug company-sponsored continuing medical education
(CME) preferentially highlighted the sponsor's drug(s) compared
with other CME programs.
Attending sponsored CME events and accepting funding for
travel or lodging for educational symposia were associated with in-
creased prescription rates of the sponsor's medication.
Attending presentations given by pharmaceutical representa-
tive speakers was also associated with non-rational prescribing."3
In Commentary published in the same issue as the study, Dr.
Robert M. Tenery notes that many doctors are not even aware of
the extent of influence that industry-sponsored activities and gifts
have on their prescribing practices."4 He advocates that:
Even though it may be desirable to encourage informa-
tion sharing, relationships between physicians and indus-
try raise concerns about whether the patient's best inter-
ests will come into conflict with industry's focus on the
bottom line. Physicians should not take as absolute every-
thing they are told by industry representatives and should
become cognizant of the potential conflicts created by the
increasing level of sophistication in the detailing tech-
niques used by these individuals.' |5
112. Ashley Wazana, M.D., Physicians and the Pharmaceutical Industry: Is a Gift
EverJust a Gift?, 283 JAMA 373 (2000).
113. Id. at 375-377.
114. Robert M. Tenery, Jr., M.D. Interactions Between Physicians and the Health
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B. Expanding The Sphere Of Influence: "Detailing" To Nurse
Practitioners And Physicians'Assistants
Today, manufacturers' promotional efforts extend well beyond
physicians, as seen in the discussion of direct-to-consumer advertis-
ing. But even within the medical community, doctors are no
longer the exclusive focus of drug marketers. As Nurse Practitio-
ners (NP) and Physicians' Assistants (PA) receive ever-greater pre-
scribing authority, pharmaceutical and medical device "detailers"
are targeting them with more and more, promotional efforts. Some
physicians find this a cause for concern.
While non-physician prescribers, like doctors, insist that com-
pany representatives are only one source of their information on
medical products, they are nonetheless subject to a barrage of sales
pitches. A survey by Scott-Levin Associates revealed that PAs aver-
aged 4.4 visits per week from detailers, and NPs averaged 5.2.17
These visits are only expected to increase. "8
In addition to the frequency of the visits, there is a concern
that nurse practitioners and doctors' assistants are particularly sus-
ceptible to "hard sell" efforts by medical products retailers. One
commentator claims that such "physician extenders" do not have
"the knowledge base to understand pharmacology and the com-
plexities of medicine.""9 He quips that "[t] hey are given samples of
advanced antibiotics, invited out to dinner and are being prepped
to use these samples.' ' 20 Fearing that "drug companies are simply
looking for the weakest link in the practice," he postulates that
nurse practitioners and physician assistants are being targeted be-
cause they are "most likely to comply with marketing and sales mes-
sages.
Whether non-physician prescribers are this easily swayed by de-
tailers can be argued, but there is no disputing the fundamental
shift in the demographics of medical products sales. As marketing
to non-physicians escalates, doctors are less available to company
salespeople than ever before. 22 In addition, as consumers receive
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more advertising messages about new products, they specifically re-
quest certain name-brand medications, and primary care physi-
cians, given their time constraints, are increasingly delegating such
requests to their assistants. 
23
Further, according to the Scott-Levin survey, 80% of PAs and
69% of NPs recommend new drugs to the doctors with whom they
work, 12 4 which may influence the extent to which these products are
ultimately prescribed. At the same time, Dr. Yank Coble of the
American Medical Association expressed that "I don't get my in-
formation on new drugs from nurses, and I don't think many other
doctors do either.',125 Thus, it remains unclear just how much
stepped-up marketing to non-physicians has actually influenced
prescribing practices.
It is also worth noting, however, that the increase in non-
physician prescribing, along with the intensified sales efforts di-
rected at PAs and NPs, could have dire consequences for the
learned intermediary doctrine. If it is indeed "unrealistic," as Dr.
Coble claims, "to suddenly expect people with less training than
doctors to interpret research for patients,'' 26 then courts will have
no choice but to ignore the learned intermediary doctrine and re-
quire manufacturers to provide warnings directly to consumers.
VI. REPROCESSING AND REUSE OF SINGLE USE DEVICES
With the increased cost-control pressures of managed care,
along with the ascendance of for-profit hospitals, providers today
have every incentive to cut costs wherever they can. Thus, many
providers have begun cleaning ("reprocessing") and returning to
circulation so-called "single-use" medical devices. Hospitals and
medical centers can save tens of thousands of dollars per year by
reusing such devices. 12  Further, doctors argue that the prices
manufacturers charge are so prohibitive that they cannot afford to
use a device just once, and costs cannot be passed along to patients






127. Gina Kolata, "Single Use" Medical Devices Are Often Used Several Times, N. Y.
Times, November 10, 1999.
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care. 12 Dr. David Haines of the University of Virginia Health Sys-
tem claims that if they were forced to use cardiac catheters only
once, as the manufacturer's labeling directs, "we would shift from
being marginally profitable to probably losing $600,000 a year."
Many also point to the fact that some devices initially labeled "reus-
able" were switched to "single-use" without any structural changes,
making it appear that the switch had more to do with marketing
than safety.
While Dr. Larry Kessler, director of the office of surveillance
and biometrics at FDA, acknowledges that "there's a big yuck factor
to reusing devices," he maintains that nevertheless "there are no
products where we have significant evidence that there is immedi-
ate harm to public health." ''3 Published studies by Dr. Richard A.
Kozarek, chief of gastroenterology at Virginia Mason Medical Cen-
ter in Seattle, show that various devices can safely be reused nu-
merous times, generating a substantial savings for health-care pro-
viders." Further, of the more than 100,000 yearly adverse reports
concerning devices, virtually all involve devices used just once.13
Of course, as Dr. Kessler acknowledges, if a reprocessed device
failed, "[d]o you think the hospital would want to tell anyone?
They are worried that they will be in court and in serious trou-
ble."
133
So far, FDA has refrained from requiring reprocessors of sin-
gle-use devices to prove that the products are "safe and effective"
when they leave their hands, but this may change as medical device
manufacturers are increasingly challenging the practice. 3 4 Despite
charges that the industry's complaints are motivated by their profit
margins, medical device manufacturers argue that the real issue is
patient safety. 3 5 Patricia Davis, an electrical engineer and senior
patent attorney at Boston Scientific, a leading manufacturer of
coronary stents, claims that studies by her company indicate that
devices are often contaminated and degraded when they leave the
128. Id.
129. E.g., Congressional Testimony of Vern Feltner, February 10, 2000, 2000
WL 11068076.
130. Gina Kolata, "Single Use" Medical Devices Are Often Used Several Times, N. Y.
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reprocessor.136 She warns that subtle changes in a device's function-
ing upon reuse can have devastating consequences for patients."'
Another commentator raises the concern that since single-use de-
vices are not made to be cleaned and reused, "the very design struc-
ture did not take into account the need to access all the nooks and
crannies in order to clean them.',13 This increases the risk of infec-
tion, which he claims patients should be informed of.
L 39
Robert O'Halla, Vice President of Regulatory Affairs for Medi-
cal Devices and Diagnostics atJohnson &Johnson and Chairman of
the Association of Disposable Device Manufacturers, argues that
there is no reason to treat reprocessors differently than original
equipment manufacturers (OEMs) . OEMs are required to obtain
either 510(k) clearance or pre-market approval for their single-use
devices. 141 When they are approved, they are approved for one use
only, since no data supports their safety and efficacy beyond that.
Therefore, when a reprocessor prepares a device for reuse, as a
regulatory matter this is tantamount to creating a new device."' Yet
to this point, FDA has exercised its "regulatory discretion" to not
require reprocessors to submit 510(k) or pre-market approval ap-
plications-even while recognizing that the same provisions of the
Food, Dru 4& Cosmetic act that apply to OEMs also apply to re-
processors.
Under increased pressure from manufacturers, and recogniz-
ing the inconsistency of their position, FDA is in the process of
formulating regulations for reprocessing of single-use devices. In
testimony before Congress, Dr. David Feigal, Director of FDA's
Center for Devices and Radiological Health (CDRH), indicated
that the Agency plans "a new regulatory approach that will treat
136. Gina Kolata, "Single Use" Medical Devices Are Often Used Several Times, N. Y
Times, November 10, 1999.
137. Id.
138. Congressional Testimony of Philip Grossman, M.D., February 10, 2000,
2000 WL 11068079.
139. Id.
140. Congressional Testimony of Robert H. O'Holla, February 10, 2000, 2000
WL 11068080.
141. 510(k) clearance may be obtained by showing that a new device is
"substantially similar" to one already shown to be safe and effective. See generally 21
C.F.R. § 807, Subpart E. Pre-market approval requires much more extensive test-
ing to show that the device actually is safe and effective. See generally 21 C.F.R. §
814, Subpart B.
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Original Equipment Manufacturers... third parties and hospitals in
a similar manner to minimize risks associated with reused single-use
devices.'1 4 For now, FDA is receiving comments on its February 8,
2000 draft Guidance which presents a "Review Prioritization
Scheme" for assessing the safety of reprocessing different categories
of devices.145 Through a series of flow charts, devices will be charac-
terized as low, medium, and high risk for reprocessing based on
answers to questions like:
Does postmarket information suggest that using the reproc-
essed SUD [(single-use device)] may present an increased risk of
infection when compared to the use of a SUD that has not been
reprocessed?
Does the SUD include features that could impede thorough
cleaning and adequate sterilization/disinfection?1
46
Other countries are also evaluating the use of single-use de-
vices. Canada is conducting a review of the practice after the prov-
ince of Manitoba instituted a ban on hospital reprocessing. 4' Bel-
gium is considering a ban on reuse of angioplasty balloons,
electrophysiology catheters, biopsy forceps and other delicate de-141
vices used in invasive procedures. In the United Kingdom, the
Medical Device Agency has taken a stance against reuse due to a
concern with the transmission of Creutzfeld-Jakob or "mad cow"
disease.
149
Of course, while reprocessors face liability for contaminated
devices that leave their cleaning facilities, manufacturers may ulti-
mately bear more of the burden for injuries resulting from failures
of reprocessed devices. When reports of injuries from reused de-
vices started to accumulate, instead of questioning reprocessors on
the adequacy of their procedures, FDA suggested that OEMs
should compile data on risks associated with reprocessing and re-
use. 50 In addition, since manufacturers will often more capitalized
144. Congressional Testimony of David W. Feigal, February 10, 2000, 2000 WL
11068073.
145. Guidance for Industry and FDA Reviewers, Reprocessing and Reuse of Single-
Use Devices: Review Prioritization Scheme (February 8, 2000), www.fda.gov/cdrh-
reuse/cdrh/reuse/1 156.pdf.
146. Id.
147. Canada Examining Single-Use Device Reuse Activity, International Regs, The
Gray Sheet, 2000 WL 8529412 (February 28, 2000).
148. Id.
149. Id.
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than reprocessing operations, they will inevitably be a target in liti-
gation stemming from such injuries. Finally, manufacturers could
be found negligent for not guarding against "foreseeable misuse"
by providing instructions for proper cleaning, and for not making
devices sturdy enough for reuse-notwithstanding the "single use
only" warning-because they will usually have actual or constructive
knowledge that purchasers are reusing their products. Whether
the medical manufacturing industry can reduce this exposure by
pressuring FDA to adopt "pre-market approval" regulations, requir-
ing reprocessors to prove the safety and efficacy of reused devices,
remains to be seen.
VII. CONCLUSION
The future of drug and medical device litigation promises to
be as contentious as the past, although the issues have changed.
Where the last 50 years saw the growth of the law with respect to
the healthcare product, in the future-as this discussion has shown
-new developments in the law will come more from the relation-
ships surrounding the product: between industry and the con-
sumer, between physician and industry, between industry and the
FDA, and even between rival healthcare industries. What will re-
main unchanged, however, is the intensity of the conflict as the law
struggles to reconcile itself with the new realities of medical tech-
nology in the 21i t Century.
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